-
My Account
co-presented by
ASSOCIATE SPONSORS
In App
My Account
co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
BSE Live
Mar 14, 16:00Prev. Close
396.55
Open Price
395.10
Bid Price (Qty.)
395.00 (1000)
Offer Price (Qty.)
396.55 (187)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Cash Flow of Claris Lifesciences (in Rs. Cr.) | Mar 17 | Mar 16 | Mar 15 | Dec 13 | Dec 12 | |
| 12 mths | 12 mths | 15 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 7.39 | 39.29 | 107.22 | 103.21 | 106.28 | |
| Net CashFlow From Operating Activities | -42.14 | -71.98 | 48.58 | 121.96 | 247.75 | |
| Net Cash Used In Investing Activities | 28.02 | 125.02 | 233.97 | 217.22 | -340.98 | |
| Net Cash Used From Financing Activities | -8.91 | -28.93 | -329.78 | -342.78 | 51.12 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -23.04 | 24.10 | -47.23 | -3.60 | -42.11 | |
| Cash And Cash Equivalents Begin of Year | 45.20 | 21.10 | 68.33 | 71.93 | 114.04 | |
| Cash And Cash Equivalents End Of Year | 22.16 | 45.20 | 21.10 | 68.33 | 71.93 |
03.12.2017
17.10.2017
31.07.2017
US FDA conducts surprise audit at Claris Life's Ahmedabad unit
27.07.2017
Claris completes injectables biz sale, to inform about transfer to shareholders by Oct
